Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

This cohort study investigates the immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis who had a weak immune response to COVID-19 vaccination.

Detalles Bibliográficos
Autores principales: König, Marton, Torgauten, Hilde Marie, Tran, The Trung, Holmøy, Trygve, Vaage, John Torgils, Lund-Johansen, Fridtjof, Nygaard, Gro Owren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787678/
https://www.ncbi.nlm.nih.gov/pubmed/35072702
http://dx.doi.org/10.1001/jamaneurol.2021.5109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787678/
https://www.ncbi.nlm.nih.gov/pubmed/35072702
http://dx.doi.org/10.1001/jamaneurol.2021.5109

Ejemplares similares